Top

Current Hepatology Reports

Published in:

01-12-2017 | Fatty Liver Disease (S Harrison and J George, Section Editors)

Non-alcoholic Fatty Liver Disease in Non-obese Patients

Authors: Christopher J. Schmoyer, Mohammad S. Siddiqui

Published in: Current Hepatology Reports | Issue 4/2017

Abstract

Purpose of Review

Non-alcoholic fatty liver disease has quickly become the most common cause of liver disease. Interestingly, a cohort of patients has been identified with NAFLD who are of a normal body mass index. This review focuses on the current understanding of NAFLD among non-obese individuals.

Recent Findings

Advances in understanding the risk factors for non-obese non-alcoholic fatty liver disease and its link to visceral adiposity have increased our knowledge of this disease. Also, preliminary data notes an association with alterations in the gut microbiota and the effect of dietary habits on fatty liver disease in the non-obese population.

Summary

Non-obese NAFLD is a pervasive and likely underdiagnosed entity that seems to have similar risk factors and characteristics to fatty liver disease in the obese population. Still, non-obese NAFLD remains poorly understood.

Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, et al. Changes in the prevalence of the most commons causes of chronic liver diseases in the United States from 1998 to 2008. Clin Gastroenterol Hepatol. 2011;9(6):524–30. https://doi.org/10.1016/j.cgh.2011.03.020.PubMedCrossRef

Le MH, Devaki P, Ha NB, Jun DW, Te HS, Cheung RC, et al. Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States. PLoS One. 2017;12(3):e0173499. https://doi.org/10.1371/journal.pone.0173499.PubMedPubMedCentralCrossRef

Benedict M, Zhang X. Non-alcoholic fatty liver disease: an expanded review. World J Hepatol. 2017;9(16):715–32. https://doi.org/10.4254/wjh.v9.i16.715.PubMedPubMedCentralCrossRef

Moore JX, Chaudhary N, Akinyemiju T. Metabolic syndrome prevalence by race/ethnicity and sex in the United States, national health and nutrition examination survey, 1988-2012. Prev Chronic Dis. 2017;14:E24. https://doi.org/10.5888/pcd14.160287.PubMedPubMedCentralCrossRef

Armstrong MJ, Houlihan DD, Newsome PN. NAFLD is underrecognized in the primary care setting: UK experience. Am J Gastroenterol. 109(9):1500–1. https://doi.org/10.1038/ajg.2014.207.

Blais P, Husain N, Kramer JR, Kowalkowski M, El-Serag H, Kanwal F. Nonalcoholic fatty liver disease is underrecognized in the primary care setting. Am J Gastroentrerol. 2015;110(1):10–4. https://doi.org/10.1038/ajg.2014.134.CrossRef

Younossi ZM, Blissett D, Blissett R, Henry L, Setpanova M, Younossi Y, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64(5):1577–86. https://doi.org/10.1002/hep.28785.PubMedCrossRef

Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142(7):1592–609. https://doi.org/10.1053/j.gastro.2012.04.001.PubMedCrossRef

Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–21.PubMedCrossRef

10.

11.

Bedossa P, Poitou C, Veyrie N, Bouillot JL, Basdevant A, Paradis V, et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology. 2012;56(5):1751–9. https://doi.org/10.1002/hep.25889.PubMedCrossRef

12.

Adams LA, Lymp JF, St Sauver J, Ssanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population based cohort study. Gastroenterology. 2005;129(1):113–21.PubMedCrossRef

13.

Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmgvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44(4):865–73.PubMedCrossRef

14.

Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with non-alcoholic fatty liver disease. Gastroenterology. 2015;149(2):389–97. https://doi.org/10.1053/j.gastro.2015.04.043.PubMedPubMedCentralCrossRef

15.

Soderberg C, Stal P, Askling J, Glaumann H, Lindberg G, Marmur J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology. 2010;51(2):595–602. https://doi.org/10.1002/hep.23314.PubMedCrossRef

16.

Margariti A, Deutsch M, Manolakopoulos S, Tiniakos D, Papatheodoridis GV. The severity of histologic liver lesions is independent of body mass index in patients with nonalcoholic fatty liver disease. J Clin Gastroenterol. 2013;47(3):280–6. https://doi.org/10.1097/MCG.0b013e31826be328.PubMed

17.

Vos B, Moreno C, Nagy N, Fery F, Cnop M, Vereerstraeten P, et al. Lean non-alcoholic fatty liver disease (Lean-NAFLD): a major cause of cryptogenic liver disease. Acta Gastroenterol Belg. 2011;74(3):389–94.PubMed

18.

Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37(4):917–23.PubMedCrossRef

19.

Kim HJ, Kim HJ, Lee KE, Kim DJ, Kim SK, Ahn CW, et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med. 2004;164(19):2169–75.PubMedCrossRef

20.

Chen CH, Huang MH, Yang JC, Nien CK, Yang CC, Yeh YH, et al. Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of Taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. J Clin Gastroenterol. 2006;40(8):745–52.PubMedCrossRef

21.

Xu C, Yu C, Ma H, Xu L, Miao M, Li Y. Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population: the Zhejiang Zhenhai Study. Am J Gastroenterol. 2013;108(8):1299–304. https://doi.org/10.1038/ajg.2013.104.PubMedCrossRef

22.

Cho HC. Prevalence and factors associated with nonalcoholic fatty liver disease in a nonobese Korean population. Gut Liver. 2016;10(1):117–25. https://doi.org/10.5009/gnl14444.PubMedPubMedCentralCrossRef

23.

Sinn DH, Gwak GY, Park HN, Kim JE, Min YW, Kim KM, et al. Ultrasonographically detected non-alcoholic fatty liver disease is an independent predictor for identifying patients with insulin resistance in non-obese, non-diabetic middle-aged Asian adults. Am J Gastrenterol. 2012;107(4):561–7. https://doi.org/10.1038/ajg.2011.400.CrossRef

24.

Kumar R, Rastogi A, Sharma MK, Bhatia V, Garg H, Bihari C, et al. Clinicopathological characteristics and metabolic profiles of non-alcoholic fatty liver disease in Indian patients with normal body mass index: do they differ from obese or overweight non-alcoholic fatty liver disease? Indian J Endocrinol Metab. 2013;17(4):655–71. https://doi.org/10.4103/2230-8210.113758.CrossRef

25.

Bhat G, Baba CS, Pandey A, Kumari N, Choudhuri G. Insulin resistance and metabolic syndrome in nonobese Indian patients with non-alcoholic fatty liver disease. Trop Gastroenterol. 2013;34(1):18–24.PubMedCrossRef

26.

Margariti E, Deutsch M, Manolakopoulos S, Papatheodoridis GV. Non-alcoholic fatty liver disease may develop in individuals with normal body mass index. Ann Gastroenterol. 2012;25(1):45–51.PubMedPubMedCentral

27.

Akyuz U, Yesil A, Yilmaz Y. Characterization of lean patients with nonalcoholic fatty liver disease: potential role of high hemoglobin levels. Scand J Gastroenterol. 2015;50(3):341–6. https://doi.org/10.3109/00365521.2014.983160.PubMedCrossRef

28.

Lankarani KB, Ghaffarpasand F, Mahmoodi M, Lofti M, Zamiri N, Heydari ST, et al. Non alcoholic fatty liver disease in southern Iran: a population based study. Hepat Mon. 2013;13(5):e9248. https://doi.org/10.5812/hepatmon.9248.PubMedPubMedCentral

29.

•• Younossi ZM, Stepanova M, Negro F, Hallaji S, Younossi Y, Lam B, et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore). 2012;91(6):319–27. https://doi.org/10.1097/MD.0b013e3182779d49. Prevalence and risk factors for non-obese NAFLD in North America. CrossRef

30.

Aneni EC, Oni ET, Martin SS, Blaha MJ, Agatston AS, Feldman T, et al. Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardiometabolic risk. J Hypertens. 2015;33(6):1207–14. https://doi.org/10.1097/HJH.0000000000000532.PubMedCrossRef

31.

Physical status: the use and interpretation of anthropometry. Report of a WHO expert Committee. World Health Organ Tech Rep Ser. 1995;854:1–452.

32.

WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157–63.CrossRef

33.

Stefan N, Schick F, Haring HU. Causes, characteristics, and consequences of metabolically unhealthy normal weight humans. Cell Metab. 2017;26(2):292–300. https://doi.org/10.1016/j.cmet.2017.07.008.PubMedCrossRef

34.

Boyko EJ, Fujimoto WY, Leonetti DL, Newel-Morris L. Visceral adiposity and risk of type 2 diabetes: a prospective study among Japanese Americans. Diabetes Care. 2000;23(4):465–71.PubMedCrossRef

35.

Despres JP, Lemieux S, Lemarche B, Prud’homme D, Moorjani S, Brun LD, et al. The insulin resistance-dyslipidemic syndrome: contribution of visceral obesity and therapeutic implications. Int J Obes Relat Metabl Disord. 1995;19(Suppl 1):S76–86.

36.

Lee SW, Son JY, Kim JM, Hwang SS, Han JS, Heo JN. Body fat distribution is more predictive of all-cause mortality than overall adiposity. Diabetes Obes Metab. 2017:July3; https://doi.org/10.1111/dom.13050.

37.

Naboush A, Hamdy O. Measuring visceral and hepatic fat in clinical practice and clinical research. Endocr Pract. 2013;19(4):587–9. https://doi.org/10.4158/EP12331.OR.PubMedCrossRef

38.

Swainson MG, Batterham AM, Tsakirides C, Rutherford ZH, Hind K. Prediction of whole-body fat percentage and visceral adipose tissue mass from five anthropometric variables. PLoS One. 2017;12(5):e0177175. https://doi.org/10.1371/journal.pone.0177175.PubMedPubMedCentralCrossRef

39.

Shaikh S, Jones-Smith J, Schulze K, Ali H, Christian P, Shamim AA, et al. Excessive adiposity at low BMI levels among women in rural Bangladesh. J Nutr Sci. 2016;5:e11. https://doi.org/10.1017/jns.2015.32.PubMedPubMedCentralCrossRef

40.

Misra A, Anoop S, Gulati S, Mani K, Bhatt SP, Pandey RM. Body fat patterning, hepatic fat and pancreatic volume of non-obese Asian Indians with type 2 diabetes in north India: a case-control study. PLoS One. 2015;10(10):e0140447. https://doi.org/10.1371/journal.pone.0140447.PubMedPubMedCentralCrossRef

41.

• Fracanzani AL, Petta S, Lombardi R, Pisano G, Russello M, Consonni D, et al. Liver and cardiovascular damage in patients with lean non-alcoholic fatty liver disease, and association with visceral obesity. Clin Gastroenterol Hepatol. 2017; https://doi.org/10.1016/j.cgh.2017.04.045. Visceral adiposity rather than BMI correlates with NAFLD and features of MetS.

42.

Ha Y, Seo N, Shim JH, Kim SY, Park JA, Han S, et al. Intimate association of visceral obesity with non-alcoholic fatty liver disease in healthy Asians: a case-control study. J Gastroenterol Hepatol. 2015;30(11):1666–72. https://doi.org/10.1111/jgh.12996.PubMedCrossRef

43.

Sookoian S, Pirola CJ. PNPLA3, the triacylglycerol synthesis/hydrolysis/storage dilemma, and nonalcoholic fatty liver disease. World J Gastroenterol. 2012;18(42):6018–26. https://doi.org/10.3748/wjg.v18.i42.6018.PubMedPubMedCentralCrossRef

44.

Severson TJ, Besur S, Bonkovsky HL. Genetic factors that affect nonalcoholic fatty liver disease: a systematic clinical review. World J Gastroenterol. 2016;22(29):6742–56. https://doi.org/10.3748/wjg.v22.i29.6742.PubMedPubMedCentralCrossRef

45.

Smagris E, BasuRay S, Li J, Huang Y, Lai KM, Gromada J, et al. Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology. 2015;61(1):108–18. https://doi.org/10.1002/hep.27242.PubMedCrossRef

46.

Romeo S, Kozlitina J, Xing C, Persemlidis A, Cox D, Pennacchio LA, et al. Genetic variation of PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40(12):1461–5. https://doi.org/10.1038/ng.257.PubMedPubMedCentralCrossRef

47.

Shen J, Wong GL, Chan HL, Chan HY, Yeung DK, Chan RS, et al. PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome. Aliment Pharmacol Ther. 2014;39(5):532–9. https://doi.org/10.1111/apt.12609.PubMedCrossRef

48.

•• Feldman A, Eder SK, Felder TK, Kedenko L, Paulweber B, Stadlmayr A, et al. Clinical and metabolic characterization of lean Caucasian subjects with non-alcoholic fatty liver disease. Am J Gastroenterol. 2017;112(1):102–10. https://doi.org/10.1038/ajg.2016.318. Carrier rates of gene mutations between obese and non-obese NAFLD. PubMedCrossRef

49.

Iglesias A, Arranz M, Alvarez JJ, Perales J, Villar J, Herrera E, et al. Cholesteryl ester transfer protein in liver disease and cholestasis, and its relation with fatty acid composition of lipoprotein lipids. Clin Chim Acta. 1996;248(2):157–74.PubMedCrossRef

50.

Shinkai H. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases. Vasc Health Risk Manag. 2012;8:323–31. https://doi.org/10.2147/VHRM.S25238.PubMedPubMedCentralCrossRef

51.

Lin S, Dai R, Lin R. A meta-analytic evaluation of cholesteryl ester transfer protein (CETP) C-629A polymorphism in association with coronary heart disease risk and lipid changes. Oncotarget. 2017;8(2):2153–63. 10.18632/oncotarget.12898.PubMed

52.

Adams LA, Marsh JA, Ayonrinde OT, Olynyk KJ, Ang WQ, Beilin LJ, et al. Cholesteryl ester transfer protein gene polymorphisms increase the risk for fatty liver in females independent of adiposity. J Gastroenterol Hepatol. 2012;27(9):1520–7. https://doi.org/10.1111/j.1440-1746.2012.07120.x.PubMedCrossRef

53.

Liaw YW, Yin CY, Lai YS, Yang TC, Wang CJ, Whang-Peng J, et al. A vaccine targeted at CETP alleviates high fat and high cholesterol diet-induced atherosclerosis and non-alcoholic steatohepatitis in rabbit. PLoS One. 2014;9(12):e111529. https://doi.org/10.1371/journal.pone.0111529.PubMedPubMedCentralCrossRef

54.

Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, et al. Evacetrapib and cardiovascular outcomes in high-risk disease. N Engl J Med. 2017;376(20):1933–42. https://doi.org/10.1056/NEJMoa1609581.PubMedCrossRef

55.

Corbin KD, Zeisel SH. Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression. Curr Opin Gastroenterol. 2012;28(2):159–65. https://doi.org/10.1097/MOG.0b013e32834e7b4b.PubMedPubMedCentralCrossRef

56.

Noga AA, Zhao Y, Vance DE. An unexpected requirement for phosphatidylethanolamine N-methyltransferase in the secretion of very low density lipoproteins. J Biol Chem. 2002;277(44):42358–65.PubMedCrossRef

57.

Song J, da Costa KA, Fischer LM, Kohlmeier M, Kwock L, Wang S, et al. Polymorphism of the PEMT gene and susceptibility to nonalcoholic fatty liver disease (NAFLD). FASEB J. 2005;19(10):1266–71.PubMedPubMedCentralCrossRef

58.

Nakatsuka A, Matsuyama M, Yamaguchi S, Katayama A, Eguchi J, Murakami K, et al. Insufficiency of phosphatidylethanolamine N-methyltransferase is risk for lean non-alcoholic steatohepatitis. Sci Rep. 2016;6:21721. https://doi.org/10.1038/srep21721.PubMedPubMedCentralCrossRef

59.

Kanwar P, Nelson JE, Yates K, Kleiner DE, Unalp-Arida A, Kowdley KV. Association between metabolic syndrome and liver histology among NAFLD patients without diabetes. BMJ Open Gastroenterol. 2016;3(1):e000114.PubMedPubMedCentralCrossRef

60.

Nakahara T, Hyogo H, Yoneda M, Sumida Y, Eguchi Y, Fugii H, et al. Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. J Gastroenterol. 2014;49(11):1477–84. https://doi.org/10.1007/s00535-013-0911-1.PubMedCrossRef

61.

Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol. 2009;104(4):861–7. https://doi.org/10.1038/ajg.2009.67.PubMedCrossRef

62.

Feldman A, Eder SK, Felder TK, Kedenko L, Paulweber B, Stadlmayr A, et al. Clinical and metabolic characterization of lean Caucasian subjects with non-alcoholic fatty liver disease. Am J Gastroenterol. 2017;112(1):102–10. https://doi.org/10.1038/ajg.2016.318.PubMedCrossRef

63.

•• Sookoian S, Pirola CJ. Systematic review and meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese subjects. Aliment Pharmacol Ther. 2017;46(2):85–95. https://doi.org/10.1111/apt.14112. Meta-analysis summarizing risk factors for NAFLD among both obese and non-obese populations. PubMedCrossRef

64.

Tune JD, Goodwill AG, Sassoon DJ, Mather KJ. Cardiovascular consequences of metabolic syndrome. Transl Res. 2017;183:57–70. https://doi.org/10.1016/j.trsl.2017.01.001.PubMedCrossRef

65.

Di Costanzo A, D’Erasmo L, Polimeni L, Baratta F, Coletta P, Di Martino M, et al. Non-alcoholic fatty liver disease and subclinical atherosclerosis: a comparison of metabolically-versus genetically-driven excess fat hepatic storage. Atherosclerosis. 2017;257:232–9. https://doi.org/10.1016/j.atherosclerosis.2016.12.018.PubMedCrossRef

66.

Danaei G, Lawes CM, Vander Hoorn S, Murray CJ, Ezzati M. Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: comparative risk assessment. Lancet. 2006;368(9548):1651–9.PubMedCrossRef

67.

Romero-Gomez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity, and exercise. J Hepatol. 2017;S0168-8278(17):32052–4. https://doi.org/10.1016/j.jhep.2017.05.016.

68.

Omagari K, Kato S, Tsuneyama K, Inohara C, Kuroda Y, Tsukuda H, et al. Effects of a long-term high-fat diet and switching from a high-fat to low-fat, standard diet on hepatic fat accumulation in Sprague-Dawley rats. Dig Dis Sci. 2008;53(12):3206–12. https://doi.org/10.1007/s10620-008-0303-1.PubMedCrossRef

69.

Ferramosca A, Zara V. Modulation of hepatic steatosis by dietary fatty acids. World J Gastroenterol. 2014;20(7):1746–55. https://doi.org/10.3748/wjg.v20.i7.1746.PubMedPubMedCentralCrossRef

70.

Kainuma M, Fujimoto M, Sekiya N, Tsuneyama K, Cheng C, Takano Y, et al. Cholesterol-fed rabbit as a unique model of nonalcoholic, nonobese, non-insulin-resistant fatty liver disease with characteristic fibrosis. J Gastroenterol. 2006;41(10):971–80. https://doi.org/10.1007/s00535-006-1883-1.PubMedCrossRef

71.

Abid A, Taha O, Nseir W, Farah R, Grosovski M, Assy N. Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome. J Hepatol. 2009;51(5):918–24. https://doi.org/10.1016/j.jhep.2009.05.033.PubMedCrossRef

72.

Assy N, Nasser G, Kamayse I, Nseir W, Beniashvili Z, Djibre A, et al. Soft drink consumption linked with fatty liver in the absence of traditional risk factors. Can J Gastroenterol. 2008;22(10):811–6.PubMedPubMedCentralCrossRef

73.

Moore JB, Gunn PJ, Fielding BA. The role of dietary sugars and de novo lipogenesis in non-alcoholic fatty liver disease. Nutrients. 2014;6(12):5679–703. https://doi.org/10.3390/nu6125679.PubMedPubMedCentralCrossRef

74.

Kontou M, Weidemann W, Bork K, Horstkorte R. Beyond glycosylation: sialic acid precursors act as signaling molecules and are involved in cellular control of differentiation of PC12 cells. Biol Chem. 2009;390(7):575–9. https://doi.org/10.1515/BC.2009.058.PubMedCrossRef

75.

Schauer R. Achievements and challenges of sialic acid research. Glycoconj J. 2000;17(7–9):485–99.PubMedCrossRef

76.

Bauer J, Osborn HM. Sialic acids in biological and therapeutic processes: opportunities and challenges. Future Med Chem. 2015;7(16):2285–99. https://doi.org/10.4155/fmc.15.135.PubMedCrossRef

77.

Manhardt CT, Punch PR, Dougher CWL, Lau JTY. Extrinsic sialylation is dynamically regulated by systemic triggers in vivo. J Biol Chem. 2017 Advance online publication; https://doi.org/10.1074/jbc.C117.795138.

78.

Browning LM, Jebb SA, Mishra GD, Cooke JH, O’Connell MA, Crook MA, et al. Elevated sialic acid, but not CRP, predicts features of the metabolic syndrome independently of BMI in women. Int J Obes Relat Metab Disord. 2004;28(8):1004–10.PubMedCrossRef

79.

Rajappa M, Ikkruthi S, Nandeesha H, Satheesh S, Sundar I, Ananthanarayanan PH, et al. Relationship of raised serum total and protein bound sialic acid levels with hyperinsulinemia and indices of insulin sensitivity and insulin resistance in non-diabetic normotensive obese subjects. Diabetes Metab Syndr. 2013;7(1):17–9. https://doi.org/10.1016/j.dsx.2013.02.030.PubMedCrossRef

80.

Tomino Y, Yagame M, Nomoto Y, Sakai H, Ito K, Nagaoka K, et al. Measurement of sialic acid and acute phase reactant proteins in sera of patients with diabetic nephropathy. J Diabet Complicat. 1988;2(4):175–8.CrossRef

81.

Tseke P, Grapsa E, Stamatelopoulos K, Samouilidou E, Rammos G, Papamichael C, et al. Correlations of sialic acid with markers of inflammation, atherosclerosis and cardiovascular events in hemodialysis patients. Blood Purif. 2008;26(3):261–6. https://doi.org/10.1159/000124850.PubMedCrossRef

82.

• Lu Z, Ma H, Xu C, Shao Z, Can C, Li Y. Serum sialic acid is significantly associated with nonalcoholic fatty liver disease in a nonobese Chinese population: a cross-sectional study. Biomed Res Int. 2016:5921589. https://doi.org/10.1155/2016/5921589. Correlation of elevated sialic acid with non-obese NAFLD.

83.

Lu Z, Ma H, Xu C, Shao Z, Cen C, Li Y. Serum sialic acid level is significantly associated with nonalcoholic fatty liver disease in a nonobese Chinese population: a cross-sectional study. Biomed Res Int. 2016:5921589. https://doi.org/10.1155/2016/5921589.

84.

Ibrahim MA, Abdulkadir A, Onojah A, Sani L, Adamu A, Abdullahi H. Modulation of sialic acid levels among some organs during insulin resistance or hyperglycemic states. Mol Cell Biochem. 2016;41(1):235–9. https://doi.org/10.1007/s11010-015-2585-x.CrossRef

85.

Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol. 2016;14(8):e1002533. https://doi.org/10.1371/journal.pbio.1002533.PubMedPubMedCentralCrossRef

86.

Wang M, Monaco MH, Donovan SM. Impact of early gut microbiota on immune and metabolic development and function. Semin Fetal Neonatal Med. 2016;21(6):380–7. https://doi.org/10.1016/j.siny.2016.04.004.PubMedCrossRef

87.

Thaiss CA, Zmora N, Levy M, Elinay E. The microbiome and innate immunity. Nature. 2016;535(7610):65–74. https://doi.org/10.1038/nature18847.PubMedCrossRef

88.

LeBlanc JG, Milani C, de Giori GS, Sesma F, van Sinderen D, Ventura M. Bacteria as vitamin suppliers to their host: a gut microbiota perspective. Curr Opin Biotechnol. 2013;24(2):160–8. https://doi.org/10.1016/j.copbio.2012.08.005.PubMedCrossRef

89.

Rowland I, Gibson G, Heinken A, Scott K, Swann J, Thiele I, et al. Gut microbiota functions: metabolism of nutrients and other food components. Eur J Nutr. 2017: Apr 9; https://doi.org/10.1007/s00394-017-1445-8.

90.

Leung C, Rivera L, Furness JB, Angus PW. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol. 2016;13(7):412–25. https://doi.org/10.1038/nrgastro.2016.85.PubMedCrossRef

91.

The Human Microbiome Project Consortium. Structure, function, and diversity of the healthy human microbiome. Nature. 2012;486(7402):207–14. https://doi.org/10.1038/nature11234.PubMedCentralCrossRef

92.

Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, et al. A core gut microbiome in obese and lean twins. Nature. 2009;457(7228):480–4. https://doi.org/10.1038/nature07540.PubMedCrossRef

93.

Backhed F, Ding H, Want T, Hooper LV, Koh GY, Nagy A, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A. 2004;101(44):15718–23.PubMedPubMedCentralCrossRef

94.

Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature. 2006;444(7122):1022–3.PubMedCrossRef

95.

Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology. 2013;57(2):601–9. https://doi.org/10.1002/hep.26093.PubMedCrossRef

96.

Mouzaki M, Comelli EM, Arendt BM, Bonengel J, Fung SK, Fischer SE, et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology. 2013;58(1):120–7. https://doi.org/10.1002/hep.26319.PubMedCrossRef

97.

• Wang B, Jiang X, Cao M, Ge J, Bao Q, Tang L, et al. Altered fecal microbiota correlates with liver biochemistry in nonobese patients with non-alcoholic fatty liver disease. Sci Rep. 2016;6:32002. https://doi.org/10.1038/srep32002. Fecal microbiota alterations in non-obese NAFLD. PubMedPubMedCentralCrossRef

98.

Le Roy T, Llopis M, Lepage P, Bruneau A, Rabot S, Bevilacqua C, et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut. 2013;62(12):1787–94. https://doi.org/10.1136/gutjnl-2012-303816.PubMedCrossRef

99.

Mokhtari Z, Gibson DL, Hekmatdoost A. Nonalcoholic fatty liver disease, the gut microbiome, and diet. Adv Nutr. 2017;8(2):240–52.PubMedCrossRef

100.

Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut. 2009;58(8):1091–103. https://doi.org/10.1136/gut.2008.165886.PubMedPubMedCentralCrossRef

101.

Schwiertz A, Taras D, Schafer K, Beijer S, Bos NA, Donus C, et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring). 2010;18(1):190–5. https://doi.org/10.1038/oby.2009.167.CrossRef

102.

Layden BT, Angueira AR, Brodsky M, Durai V, Lowe WL Jr. Short chain fatty acids and their receptors: new metabolic targets. Transl Res. 2013;161(3):131–40. https://doi.org/10.1016/j.trsl.2012.10.007.PubMedCrossRef

103.

Mofidi F, Poustchi J, Yari Z, Nourinayyer B, Merat S, Sharafkhah M, et al. Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomized double-blind, placebo-controlled, clinical trial. Br J Nutr. 2017;117(5):662–8. https://doi.org/10.1017/S0007114517000204.PubMedCrossRef

104.

Gao X, Zhu Y, Wen Y, Liu G, Wan C. Efficacy of probiotics in non-alcoholic fatty liver disease in adult and children: a meta-analysis of randomized controlled trials. Hepatol Res. 2016;46(12):1226–33. https://doi.org/10.1111/hepr.12671.PubMedCrossRef

105.

Wong VW, Won GL, Chim AM, Chu WC, Yeung DK, Li KC, et al. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Ann Hepatol. 2013;12(2):256–62.PubMed

106.

Aller R, De Luis DA, Izaola O, Conde R, Gonzalez Sagrado M, Primo D, et al. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci. 2011;15(9):1090–5.PubMed

107.

Malaguarnera M, Vacante M, Antic T, Giordano M, Chisari G, Acquaviva R, et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci. 2012;57(2):545–53. https://doi.org/10.1007/s10620-011-1887-4.PubMedCrossRef

108.

Athyros VG, Alexandrides TK, Bilianou H, Cholongitas E, Doumas M, Ganotakis ES, et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An expert panel statement. Metabolism. 2017;71:17–32. https://doi.org/10.1016/j.metabol.2017.02.014.PubMedCrossRef

109.

Portillo-Sanchez P, Cusi K. Treatment of nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus. Clin Diabetes Endocrinol. 2016;2:9. https://doi.org/10.1186/s40842-016-0027-7.PubMedPubMedCentralCrossRef

110.

Oh S, So R, Shida T, Matsuo T, Kim B, Akiyama K, et al. High-intensity aerobic exercise improves both hepatic fat content and stiffness in sedentary obese men with nonalcoholic fatty liver disease. Sci Rep. 2017;7:43029. https://doi.org/10.1038/srep43029.PubMedPubMedCentralCrossRef

111.

Hallsworth K, Fattakhova G, Hollingsworth KG, Thoma C, Moore S, Taylor R, et al. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut. 2011;60(9):1278–83. https://doi.org/10.1136/gut.2011.242073.PubMedPubMedCentralCrossRef

112.

Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675–85. https://doi.org/10.1056/NEJMoa0907929.PubMedPubMedCentralCrossRef

113.

Cusi K, Orsak B, Bril F, Lomonaco R, Hecht J, Ortiz-Lopez C, et al. Long-term pioglitazone for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med. 2016;165(5):305–15. https://doi.org/10.7326/M15-1774.PubMedCrossRef

Title: Non-alcoholic Fatty Liver Disease in Non-obese Patients
Authors: Christopher J. Schmoyer
Mohammad S. Siddiqui
Publication date: 01-12-2017
Publisher: Springer US
Published in: Current Hepatology Reports / Issue 4/2017
Electronic ISSN: 2195-9595
DOI: https://doi.org/10.1007/s11901-017-0377-3

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 4/2017

Biochemical and Molecular Mechanisms of Liver Damage-Induced by Antidepressant Drugs: an Update Review

Hepatotoxicity of New Antitumor Agents

Endoscopic Therapy for Variceal Bleeding: from Patient Preparation to Available Techniques and Rescue Therapies

Natural History of NAFLD/NASH

Managing HCC in NAFLD

The Management of Bleeding from Anorectal Varices

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage